These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30792003)

  • 41. Factors Predictive of 90-Day Morbidity, Readmission, and Costs in Patients Undergoing Pelvic Exenteration.
    Bogani G; Signorelli M; Ditto A; Martinelli F; Casarin J; Mosca L; Leone Roberti Maggiore U; Chiappa V; Lorusso D; Raspagliesi F
    Int J Gynecol Cancer; 2018 Jun; 28(5):975-982. PubMed ID: 29683876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urologic complications of pelvic exenteration for gynecologic malignancy.
    Fallon B; Loening S; Hawtrey CE; Lifshitz SG; Buchsbaum HJ
    J Urol; 1979 Aug; 122(2):158-9. PubMed ID: 459005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies.
    Matsuo K; Matsuzaki S; Mandelbaum RS; Matsushima K; Klar M; Grubbs BH; Roman LD; Wright JD
    J Surg Oncol; 2020 Feb; 121(2):402-409. PubMed ID: 31746006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Laparoscopy-assisted vaginal pelvic exenteration.
    Ferron G; Querleu D; Martel P; Letourneur B; Soulié M
    Gynecol Oncol; 2006 Mar; 100(3):551-5. PubMed ID: 16249020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaginal reconstruction at the time of pelvic exenteration: a surgical and psychosexual analysis of techniques.
    Mirhashemi R; Averette HE; Lambrou N; Penalver MA; Mendez L; Ghurani G; Salom E
    Gynecol Oncol; 2002 Oct; 87(1):39-45. PubMed ID: 12468340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colorectal function preservation in posterior and total supralevator exenteration for gynecologic malignancies: an 89-patient series.
    Moutardier V; Houvenaeghel G; Lelong B; Mokart D; Delpero JR
    Gynecol Oncol; 2003 Apr; 89(1):155-9. PubMed ID: 12694670
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors affecting hospital length of stay following pelvic exenteration surgery.
    Guo Y; Chang E; Bozkurt M; Park M; Liu D; Fu JB
    J Surg Oncol; 2018 Mar; 117(3):529-534. PubMed ID: 29044540
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration.
    Donati OF; Lakhman Y; Sala E; Burger IA; Vargas HA; Goldman DA; Andikyan V; Park KJ; Chi DS; Hricak H
    Eur Radiol; 2013 Oct; 23(10):2906-15. PubMed ID: 23652852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic factors in pelvic exenteration for gynecological malignancies.
    Baiocchi G; Guimaraes GC; Rosa Oliveira RA; Kumagai LY; Faloppa CC; Aguiar S; Begnami MD; Soares FA; Lopes A
    Eur J Surg Oncol; 2012 Oct; 38(10):948-54. PubMed ID: 22818842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: Analysis of risk factors predicting recurrence and survival.
    Park JY; Choi HJ; Jeong SY; Chung J; Park JK; Park SY
    J Surg Oncol; 2007 Dec; 96(7):560-8. PubMed ID: 17708548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Laparoscopy-assisted vaginal pelvic exenteration].
    Ferron G; Querleu D; Martel P; Chopin N; Soulié M
    Gynecol Obstet Fertil; 2006 Dec; 34(12):1131-6. PubMed ID: 17134933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pelvic exenteration: surgical aspects and analysis of early and late morbidity in a series of 106 patients.
    De Wever I
    Acta Chir Belg; 2011; 111(5):273-81. PubMed ID: 22191127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer.
    Roos EJ; Van Eijkeren MA; Boon TA; Heintz AP
    Int J Gynecol Cancer; 2005; 15(4):624-9. PubMed ID: 16014116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pelvic exenteration: factors associated with major surgical morbidity.
    Soper JT; Berchuck A; Creasman WT; Clarke-Pearson DL
    Gynecol Oncol; 1989 Oct; 35(1):93-8. PubMed ID: 2792911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pelvic exenteration for gynecological malignancies: an analysis of 15 cases operated on at a single institution.
    Mäenpää JU; Kangasniemi K; Luukkaala T
    Acta Obstet Gynecol Scand; 2010; 89(2):279-83. PubMed ID: 19916881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low colorectal anastomosis after radical pelvic surgery: a risk factor analysis.
    Mirhashemi R; Averette HE; Estape R; Angioli R; Mahran R; Mendez L; Cantuaria G; Penalver M
    Am J Obstet Gynecol; 2000 Dec; 183(6):1375-9; discussion 1379-80. PubMed ID: 11120499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies.
    Fotopoulou C; Neumann U; Kraetschell R; Schefold JC; Weidemann H; Lichtenegger W; Sehouli J
    J Surg Oncol; 2010 May; 101(6):507-12. PubMed ID: 20401918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pelvic exenteration for primary and recurrent gynaecological malignancies.
    de Wilt JH; van Leeuwen DH; Logmans A; Verhoef C; Kirkels WJ; Vermaas M; Ansink AC
    Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):243-8. PubMed ID: 16950559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Choices in creating continent urostomies following pelvic exenteration for gynecologic malignancies.
    Silver DF; Ashwell TR
    Gynecol Oncol; 2001 Sep; 82(3):510-5. PubMed ID: 11520148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pelvic exenteration in gynecologic oncology: Experience at the Mount Sinai Center, 1975-1992.
    Dottino PR; Segna RA; Jennings TS; Mandeli JP; Konsker K; Cohen CJ
    Mt Sinai J Med; 1995 Nov; 62(6):431-5. PubMed ID: 8692157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.